Q2 2021 13F Holders as of 30 Jun 2021
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
67,129,058
-
Total 13F shares
-
7,205,272
-
Share change
-
-215,083
-
Total reported value
-
$15,488,490
-
Price per share
-
$2.15
-
Number of holders
-
34
-
Value change
-
-$493,510
-
Number of buys
-
17
-
Number of sells
-
11
Institutional Holders of AIM ImmunoTech Inc. - Common Stock, par value $0.001 per share (AIMI) as of Q2 2021
As of 30 Jun 2021,
AIM ImmunoTech Inc. - Common Stock, par value $0.001 per share (AIMI) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
7,205,272 shares.
The largest 10 holders included
MORGAN STANLEY, VANGUARD GROUP INC, BlackRock Inc., GEODE CAPITAL MANAGEMENT, LLC, BRIDGEWAY CAPITAL MANAGEMENT, LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, DIMENSIONAL FUND ADVISORS LP, PRICE T ROWE ASSOCIATES INC /MD/, and Verition Fund Management LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q2 2021 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.